Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 27, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 625,000 ordinary shares of 25 pence each.
- Purchase Price: 1,439.65 pence per share.
- Treasury Holdings: 256,852,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,752,195,717 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on February 27, 2007, pursuant to shareholder authority granted at the Annual General Meeting on May 17, 2006. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,752,195,717) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (256,852,678) for accurate fully diluted share count calculations.
- Note that this filing is a transactional report and does not contain operational or financial performance data for the period.